Active substance
Ursodeoxycholic acid
- SFDA 2
- NHS prices 7
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| URSOFALK 250MG CAPSULE | 250 mg | Capsule · Oral use | 50 Blister | SAR 77.75 | NCE · Prescription | DR. FALK PHARMA | Valid |
| Ursofalk | 500 mg | Film-coated tablet · Oral use | 50 Blister | SAR 101.25 | NCE · Prescription | DR. FALK PHARMA | Valid |
Indications — CHI Daman Drug Formulary
AUTOIMMUNE HEPATITIS; BARIATRIC SURGERY; CYSTIC FIBROSIS; PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Ursodeoxycholic acid 150mg tablets | £96.87 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Ursodeoxycholic acid 250mg capsules | £16.68 | 60 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Ursodeoxycholic acid 250mg tablets | £18.00 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Ursodeoxycholic acid 250mg/5ml oral suspension sugar free | £26.98 | 250 ml | 1 Oct 2026 |
| NHS Drug Tariff | Ursodeoxycholic acid 300mg tablets | £85.74 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Ursodeoxycholic acid 500mg capsules | £24.00 | 60 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Ursodeoxycholic acid 500mg tablets | £87.35 | 100 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.